BioSpace News Archive

Drug Development

Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density

Transcenta Holding Limited announces that it has received approval from China Center for Drug Evaluation to initiate Phase II clinical trial of TST002.

July 30, 2023
·
5 min read
Business

Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the fourth quarter ended June 30, 2023.

July 30, 2023
·
6 min read
Biotech Bay

Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic Atrophy

Annexon, Inc. presented results from the ongoing ARCHER trial in patients with geographic atrophy, underscoring ANX007’s potentially distinct neuroprotective mechanism of action and demonstration of consistent protection from vision loss.

July 30, 2023
·
10 min read
Genetown

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

Apellis Pharmaceuticals, Inc. announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE®, the first and only FDA approved treatment for geographic atrophy secondary to age-related macular degeneration.

July 30, 2023
·
9 min read